Original Research
Published on 09 Sep 2024
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
in Cancer Immunity and Immunotherapy
- 128 views
Original Research
Published on 09 Sep 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 09 Sep 2024
in Lipids in Cardiovascular Disease
Review
Published on 09 Sep 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 09 Sep 2024
in Immunological Tolerance and Regulation
Original Research
Published on 09 Sep 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 09 Sep 2024
in Neuroendocrine Science
Original Research
Published on 09 Sep 2024
in Cancer Immunity and Immunotherapy
Review
Published on 09 Sep 2024
in Microbial Immunology
Brief Research Report
Published on 09 Sep 2024
in Social Impact of Tourism
Original Research
Published on 09 Sep 2024
Original Research
Published on 09 Sep 2024
in Sports Politics, Policy and Law
Systematic Review
Published on 09 Sep 2024
in Psychopharmacology
Original Research
Published on 09 Sep 2024
in Virtual Reality and Human Behaviour
Original Research
Published on 09 Sep 2024
in Neurogenetics
Review
Published on 09 Sep 2024
in Intensive Care Medicine and Anesthesiology
Original Research
Published on 09 Sep 2024
in Public Mental Health